3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
427
Neoplasms, Plasma Cell
68
Lymphoma, Mantle-Cell
66
Lymphoma
65
Recurrence
64
Lymphoma, Non-Hodgkin
43
Lymphoma, Follicular
42
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Leukemia, Myeloid, Acute
36
Lymphoma, Large B-Cell, Diffuse
34
Waldenstrom Macroglobulinemia
33
Lymphoma, B-Cell, Marginal Zone
30
Leukemia, Lymphocytic, Chronic, B-Cell
28
Neoplasms
24
Carcinoma, Non-Small-Cell Lung
24
Immunoglobulin Light-chain Amyloidosis
23
Leukemia
21
Hodgkin Disease
17
Lymphoma, B-Cell
14
Burkitt Lymphoma
14
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
13
Myelodysplastic Syndromes
13
Lymphoma, Large-Cell, Anaplastic
13
Hematologic Neoplasms
13
Immunoblastic Lymphadenopathy
12
Breast Neoplasms
12
Mycosis Fungoides
11
Lymphoma, T-Cell, Cutaneous
11
Lymphoma, Large-Cell, Immunoblastic
11
Congenital Abnormalities
11
Interventions
Nivolumab
2
sotrovimab
1
gusacitinib
1
ciclesonide
1
cabozantinib
1
Specimen Handling
1
Platinum Compounds
1
Niclosamide
1
Ipilimumab
1
High-Intensity Interval Training
1
Exercise
1
Cholecalciferol
1
CTLA-4 Antigen
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lupus Erythematosus, Systemic
×
Bortezomib
×
Clear all
NCT02102594
2019-12-03
TAVAB
Charite University, Berlin, Germany
Phase 2
Terminated
11 enrolled